Enforcement Report - Week of August 23, 2023
Britannia, Vifor, AbbVie, Allergan, Advanced Accelerator Applications (now owned by Novartis) and Otsuka’s Europe and U.K. business were all found in breach of a series of the PMCPA code.
Advanced Accelerator Applications USA is on Health Canada Inspection List
Enforcement Report - Week of April 13, 2022
Crinetics launched Radionetics after the closing bell Monday, the company announced, seeding the new entity with $30 million raised from 5AM Ventures and Frazier Healthcare Partners. Radionetics will start with its own radiopharma-centric platform and a pipeline of 10 programs aimed at solid tumors.
More than two years after splashing out $2.1 billion on Endocyte, Novartis is pulling the curtain on full phase 3 data for the radiopharmaceutical it picked up in that deal.
ZURICH (Reuters) - Novartis’ experimental Lu-PSMA-617 radioligand therapy has improved the survival of prostate cancer patients with a hard-to-treat form of the disease, the Swiss drugmaker said on Tuesday.
Bain Capital is deploying one of its top investors to Cerevel Therapeutics, steering a $350 million-plus neuro play carved out of Pfizer. Orly Mishan — a co-founder and principal of Bain’s life sciences unit — was involved in the partnership that birthed the biotech spinout in the first place. As Cerevel’s first chief business officer, she is tasked with corporate development, program management as well as technical operations.
Five years after Chimerix found itself at the center of a hurricane of public anger over its initial refusal to provide their lead experimental drug to a dying child, the biotech says now that they can’t even recruit patients for their studies.
Novartis has posted a 5% increase in its sales in 2018, driven up by strong performances by psoriasis blockbuster Cosentyx and heart failure drug Entresto.